Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer

Risk summary

Dendritic Cells

CONTACT US

Summary

This analysis was conducted to evaluate whether autologous cytokine-induced killer cells (CIK) or dendritic cells and cytokine-induced killer cells (DC-CIK) immunotherapy combined with chemotherapy can improve the effect and safety of chemotherapy in esophageal cancer (EC). The results show that it is infuse safe and effective for patients. Immunotherapy can significantly improve the anti tumor immune response. Finally, combination therapy enhances the immune function and improves the therapeutic efficacy of patients with EC.

Introduction

Esophageal cancer is a serious condition that can be fatal. Dendritic cells and cytokine-induced killer cells, which are both natural therapies for cancer, have been studied as potential treatment options. Dendritic cells were found to be more effective than cytokine-induced killer cells in treating esophageal cancer. This blog post discusses 8 ways these two natural therapies could help improve the quality of life for those with this disease.

Conclusion

It is safe and effective for patients to use chemotherapy combined with CIK/DC-CIK immunotherapy. Immunotherapy can simultaneously improve the antitumor immune response. Specifically, DC-CIK cells can increase T lymphocyte subsets, CIK cells, NK cells, and immunoglobulins in peripheral blood to enhance antitumor immunity. Therefore, combination therapy enhances the immune function and improves the therapeutic efficacy of patients with EC. 

Article Reference link: click here

Scientific article publishing date : 02/04/2021

Immucura identifier : BSC21_006EN

ALL SCIENTIFIC PAPERS
CONTACT US